Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma

Intern Med. 2023 Nov 15;62(22):3381-3385. doi: 10.2169/internalmedicine.1163-22. Epub 2023 Mar 31.

Abstract

Pneumocystis pneumonia (PCP) is an opportunistic infection that presents a ground-glass appearance in the lungs on chest radiography. Interstitial lung disease is a commonly reported adverse effect of immune checkpoint inhibitor (ICI) treatment; however, there are few reports of ICI treatment-associated PCP infection. A 77-year-old man with lung adenocarcinoma was administered pembrolizumab and hospitalized for dyspnea 2 weeks after treatment. Chest computed tomography showed bilateral ground-glass opacities in all lung lobes. PCP was therefore diagnosed, and steroids and sulfamethoxazole-trimethoprim were initiated. Following treatment, the patient's condition improved promptly. This report suggests that ICI treatment can cause PCP infection.

Keywords: chest X-ray; differential diagnosis; ground-glass opacity; immunotherapy; opportunistic infection; pneumocystis pneumonia.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung* / complications
  • Adenocarcinoma of Lung* / drug therapy
  • Aged
  • Humans
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / drug therapy
  • Male
  • Pneumocystis carinii*
  • Pneumonia, Pneumocystis* / chemically induced
  • Pneumonia, Pneumocystis* / diagnostic imaging
  • Pneumonia, Pneumocystis* / drug therapy

Substances

  • pembrolizumab